Xvivo Perfusion Ab Stock Price To Sales
| XVIPF Stock | USD 41.23 0.77 1.83% |
Xvivo Perfusion AB fundamentals help investors to digest information that contributes to Xvivo Perfusion's financial success or failures. It also enables traders to predict the movement of Xvivo Pink Sheet. The fundamental analysis module provides a way to measure Xvivo Perfusion's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xvivo Perfusion pink sheet.
Xvivo |
Xvivo Perfusion AB Company Price To Sales Analysis
Xvivo Perfusion's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Xvivo Perfusion Price To Sales | 16.90 X |
Most of Xvivo Perfusion's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xvivo Perfusion AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Xvivo Perfusion AB has a Price To Sales of 16.9032 times. This is 21.01% lower than that of the Healthcare sector and 253.62% higher than that of the Medical Devices industry. The price to sales for all United States stocks is 48.01% lower than that of the firm.
Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Xvivo Fundamentals
| Return On Equity | 0.0136 | |||
| Return On Asset | 0.0057 | |||
| Profit Margin | 0.04 % | |||
| Current Valuation | 536.1 M | |||
| Shares Outstanding | 29.83 M | |||
| Shares Owned By Insiders | 12.25 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Earning | 166.11 X | |||
| Price To Book | 4.58 X | |||
| Price To Sales | 16.90 X | |||
| Revenue | 258.39 M | |||
| Gross Profit | 296.96 M | |||
| EBITDA | 39.2 M | |||
| Net Income | 8.15 M | |||
| Cash And Equivalents | 22.66 M | |||
| Cash Per Share | 0.86 X | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 6.48 X | |||
| Book Value Per Share | 2.28 X | |||
| Cash Flow From Operations | (12.06 M) | |||
| Earnings Per Share | 0.10 X | |||
| Number Of Employees | 133 | |||
| Beta | 1.97 | |||
| Market Capitalization | 674.8 M | |||
| Total Asset | 1.54 B | |||
| Net Asset | 1.54 B |
About Xvivo Perfusion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xvivo Perfusion AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xvivo Perfusion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xvivo Perfusion AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.